home / stock / vtgn / vtgn news

VTGN News and Press, VistaGen Therapeutics Inc. From 11/04/21

Stock Information
Company Name: VistaGen Therapeutics Inc.
Stock Symbol: VTGN
Market: NASDAQ
Website: vistagen.com
Menu
VTGN VTGN Quote VTGN Short VTGN News VTGN Articles VTGN Message Board
Get VTGN Alerts

News, Short Squeeze, Breakout and More Instantly...
VTGN - InvestorNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Call, Release Q2 2022 Financial Report and Development Update

VistaGen Therapeutics (NASDAQ: VTGN ), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders,...
VTGN - VistaGen Therapeutics to Report Fiscal Year 2022 Second Quarter Financial Results and Recent Developments on November 10, 2021

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and oth...

VTGN - InvestorNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial

VistaGen (NASDAQ: VTGN) , a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the initiation of a phase 2A clini...

VTGN - VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder

Study Launches Phase 2A Clinical Program Designed to Explore PH94B’s Potential in Multiple Additional Anxiety Disorders Phase 2A Study in Adjustment Disorder to Run in Parallel with Ongoing Phase 3 Studies in Acute Treatment of Social Anxiety Disorder SOUTH SAN FRAN...
VTGN - InvestorNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Data on New Preclinical Mechanism of Action Regarding Potential Anti-Anxiety Activity

VistaGen Therapeutics (NASDAQ: VTGN ), a biopharmaceutical company developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has released data regarding a new me...

VTGN - VistaGen Therapeutics Reports New Preclinical Mechanism of Action Data Supporting PH94B's Potential Anti-Anxiety Activity via Peripheral Nasal Neurons without Entry into the Brain

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CN...

VTGN - InvestorNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Further Advancement of PALISADE Program for PH94B in Social Anxiety Disorder

VistaGen (NASDAQ: VTGN) , a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the initiation of PALISADE-2, the ...
VTGN - VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and oth...

VTGN - InvestorNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Baird Global Healthcare Conference

VistaGen Therapeutics (NASDAQ: VTGN ), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders,...

VTGN - VistaGen Therapeutics to Participate in Baird's 2021 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central...
Previous 10 Next 10